此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

口服地西他滨联合艾伏西地尼作为老年/不适合成年AML患者的一线治疗 (DECISIVO)

2026年9月21日 更新者:PETHEMA Foundation

一项评估口服地西他滨联合艾伏西尼在60岁以上新诊断急性髓系白血病成人患者和/或不适合标准诱导化疗患者中的疗效和安全性的II期、多中心、开放标签临床试验

The goal of this clinical trial is to learn if the combination of oral decitabine plus ivosidenib works to treat naïve adult patients with acute myeloid leukemia (AML) with IDH1 R132 mutation older than 60 years old or those who are older than 18 years old with defined comorbidities that make them not suitable for standard induction therapy. The main objectives of this clinical trial are:

  • Asses the Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) rates of this treatment.
  • Determine the incidence and severity of all adverse events (AEs).

All participants will receive oral ivosidenib and oral decitabine in treatment cycles of 28 days until disease progression, lack of clinical benefit or the end of the study. Patients who achieve CR/CRi will be elegible to receive allogeneic stem cell transplantation.

研究概览

详细说明

A total of 50 participants will be assigned to the single treatment arm which will have treatment cycles of 28 days with Ivosidenib 500 mg/orally on Days 1-28 plus oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) on days 1-5.

Hydroxiurea or maximum 1 gram/sqm of cytarabine is allowed to control hyperleukocytosis during the screening period as well as during the first two cycles of induction.

Participants will continue their study treatment until documented disease progression per Investigator assessment, unacceptable toxicity, withdrawal of consent, the subject meets other protocol criteria for discontinuation or study completion (whichever occurs first).

Participants who are considered eligible for an allogeneic stem cell transplant after achieving CR/CRi will perform a pre-transplant visit into the study, collecting MRD stats and characteristics of transplant. They will be allowed to resume ivosidenib after day +60 of transplant. The post-transplant schedule can be administered for up to 2 years. If they do not resume ivosidenib they will perform end of trial visit (and if this is not possible the pre-transplant visit will be considered as en of trial visit).

研究类型

介入性

注册 (估计的)

50

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Aveiro、葡萄牙
        • 尚未招聘
        • ULS Região de Aveiro
        • 接触:
          • Cátia Sol dos Reis
      • Funchal、葡萄牙
        • 尚未招聘
        • Hospital Central do Funchal
        • 接触:
          • Rebeca Brito
      • Lisbon、葡萄牙
        • 尚未招聘
        • Hospital Santa Maria
        • 接触:
          • Joana Brioso
      • Lisbon、葡萄牙
        • 尚未招聘
        • ULS São José
        • 接触:
          • Luís Monteiro
      • Porto、葡萄牙
        • 尚未招聘
        • Hospital Pedro Hispano
        • 接触:
          • Ilídia Moreira
      • Albacete、西班牙、02006
        • 尚未招聘
        • Complejo Hospitalario de Albacete
        • 首席研究员:
          • Jesús Lorenzo Algarra Algarra
      • Alicante、西班牙
        • 尚未招聘
        • Hospital General Universitario Dr. Balmis
        • 首席研究员:
          • Carmen Botella, Dr
      • Burgos、西班牙、09006
        • 招聘中
        • Hospital Universitario de Burgos
        • 首席研究员:
          • Jorge Labrador
      • Cáceres、西班牙
        • 招聘中
        • Hospital San Pedro Alcántara
        • 接触:
          • Juan Bergua
      • Córdoba、西班牙、14004
        • 招聘中
        • Complejo Hospitalario Regional Reina Sofía
        • 首席研究员:
          • Josefina Serrano López
      • Las Palmas、西班牙
        • 尚未招聘
        • Hospital Universitario de Gran Canaria Doctor Negrín
        • 接触:
          • Carlos Rodríguez
      • Las Palmas de Gran Canaria、西班牙
        • 尚未招聘
        • Hospital Universitario de Canarias
        • 首席研究员:
          • Carolina Lacalzada
      • Lugo、西班牙
        • 尚未招聘
        • Hospital Universitario Lucus Augusti
        • 首席研究员:
          • Aitor Abuín, Dr
      • Madrid、西班牙
        • 尚未招聘
        • H. 12 de Octubre
        • 接触:
          • Pilar Martínez Sánchez
      • Madrid、西班牙、28040
        • 尚未招聘
        • Fundación Jiménez Díaz
        • 首席研究员:
          • José Luis López Lorenzo
      • Madrid、西班牙
        • 尚未招聘
        • Hospital Univeristario Ramón y Cajal
        • 接触:
          • Pilar Herrera
      • Málaga、西班牙
        • 招聘中
        • Hospital Virgen de la Victoria
        • 接触:
          • Maria García Fortes, Dr
      • Seville、西班牙
        • 招聘中
        • Hospital Universitario Virgen Del Rocío
        • 接触:
          • Eduardo Rodríguez Arbolí
        • 首席研究员:
          • Eduardo Rodríguez Arbolí
      • Valencia、西班牙
        • 尚未招聘
        • H. Dr. Peset
        • 接触:
          • María José Sayas
        • 副研究员:
          • María Pedreño, MD
      • Valencia、西班牙
        • 招聘中
        • Hospital Universitari i Politècnic La Fe
        • 首席研究员:
          • Irene Navarro

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Morphological diagnosis of AML (WHO criteria 2022)

  2. Newly diagnosed AML.

  3. IDH1 R132 mutations (centrally assessed by PCR and NGS). A patient will be allowed to be included with local result after approval of the medical monitor.

  4. Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2 if ≥ 60 years of age, or 0 to 3 if ≥ 18 to 60 years.

  5. Age ≥ 18 years with comorbidities contraindicating intensive chemotherapy; or age ≥ 60 years.

    • ≥ 60 years of age;

    • or ≥ 18 to 60 with at least one of the following co-morbidities:

      • ECOG Performance Status of 2 or 3;
      • Cardiac history of CHF requiring treatment or Ejection Fraction ≤ 55% or chronic stable angina;
      • DLCO ≤ 65% or FEV1 ≤ 65% or significant history of chronic pulmonary obstructive;
      • Creatinine clearance ≥ 25 mL/min to < 50 ml/min
      • Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 × ULN
      • Non active/controlled prior neoplastic disease
      • Any other patient´s comorbidity or disease condition that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the PETHEMA medical monitor before study enrolment (e.g, prior MDS or MPS, high-risk cytogenetics)
  6. Patients <70 years, with favorable risk AML according to ELN will be included only if they are not candidates to standard treatment with intensive chemotherapy.

  7. Adequate renal function as demonstrated by a creatinine clearance ≥ 25 mL/min (calculated by the Cockcroft Gault formula).

  8. Adequate liver function as demonstrated by: aspartate aminotransferase (AST) ≤ 5.0 × ULN, alanine aminotransferase (ALT) ≤ 5.0 × ULN, bilirubin ≤ 2.5 × ULN (unless considered to be due to leukemic disease, in which case it should be approved by the PETHEMA medical monitor).

  9. Subject has a white blood cell count < 30 × 109/L (Hydroxyurea is permitted to meet this criterion)

  10. Female subjects must be either postmenopausal OR permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) OR Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control. Female subjects of childbearing potential must have negative results for pregnancy tests performed along the study (screening and every three cycles). A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.

  11. Male subjects who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception.

  12. Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.

Exclusion Criteria:

  1. Subject has history of myeloproliferative neoplasm [MPN] with BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
  2. Prior therapy for AML (except hydroxiurea).
  3. Genetic diagnosis of acute promyelocytic leukemia.
  4. Subject is known to be positive for HIV (HIV testing is not required.)
  5. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required).
  6. Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients that in the opinion of the investigator would adversely affect his/her participating in this study.
  7. Any severe uncontrolled systemic infection.
  8. Subject has a history of other malignancies within 1 year prior to study entry which is not controlled and/or requiring active therapy which may compromise the administration of IVO and oral decitabine.
  9. Creatinine clearance <25 mL/min (calculated by the Cockcroft-Gault formula).
  10. Inadequate liver function as demonstrated by AST or ALT > 5.0 × ULN, or bilirubin > 2.5 × ULN (unless considered to be due to leukemic disease, in which case it should be approved by the PETHEMA medical monitor)
  11. Subject has a white blood cell count > 30 × 109/L that is not controlled using hydrea or 1 gr/sqm/day per 1 day of cytarabine.
  12. Contraindications for IVO or oral decitabine according to the SmPC.
  13. Patient has a heart rate-corrected QT interval using Fridericia's method QT for corrected heart rate (QTcF) ≥450 msec or any other factor that increases the risk of QT prolongation or arrhythmic events (e.g., hypokalemia, family history of long QT interval syndrome). Patients with prolonged QTcF interval in the setting of bundle branch block may participate in the trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Decitabine+Ivosidenib

Participants will receive treatment cycles of 28 days with Ivosidenib 500 mg/orally on Days 1-28 plus oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) on days 1-5. Hydroxiurea or maximum 1 gram/sqm of cytarabine is allowed to control hyperleukocytosis during the screening period as well as during the first two cycles of induction.

Participants who achieve CR/CRi can be submitted to allogeneic stem cell transplant and will be allowed to resume ivosidenib after day +60 of transplant. The post-transplant schedule can be administered for up to 2 years.

Oral Decitabine (Decitabine/Cedazuridine 35 Mg-100 Mg) will be administerd on Days 1-5 of each treatment cycle

Ivosidenib 500 mg/orally on Days 1-28 of each treatment cycle

0.5-6 gram/day orally during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis

Maximum 1 gram/sqm/day during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis

Only for those participants achieving CR/CRi

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Rate of CR/CRi
大体时间:3 years

To assess the rates of Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) of participants treated with Ivosidenib plus Decitabine

3 years

次要结果测量

结果测量
措施说明
大体时间
Rate CR/CRi compared to historical cohort
大体时间:3 years

To evaluate the CR (Complete Remission)/CRi (Complete Remission with incomplete marrow recovery) rates after 2, 3 and 6 cycles of Ivosidenib and oral Decitabine, and compare with a matched historical cohort.

3 years
OS compared to historical cohort
大体时间:3 years

To assess OS (overall survival, measured as the number of days from the date of enrollment to the date of death, whatever the cause of death) and compare the median between Ivosidenib with oral Decitabine and a matched historical cohort.

3 years
EFS compared to historical cohort
大体时间:3 years

To evaluate EFS (event-free survival, defined as the number of days from enrollment until the date of progressive disease, relapse from CR or CRi, failure to achieve CR or CRi, or death from any cause) and compare with a matched historical control cohort

3 years
Hematologic and non-hematologic toxicity and AE
大体时间:3 years

Toxicity and adverse events (AE) will be recorded and evaluated to determine treatment safety. Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.019.

3 years
Quality of CR
大体时间:3 years

The quality of the Complete Remission (CR) will measured by the study of minimal residual disease percentages in the bone marrow using multiparametric flow cytometry and Next Generation Sequencing

3 years
Early mortality
大体时间:3 years

To evaluate the mortality rate during the first 60 days of treatment

3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Pau Montesinos、Hospital Universitari i Politèncic La Fe

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月12日

初级完成 (估计的)

2029年4月1日

研究完成 (估计的)

2029年4月1日

研究注册日期

首次提交

2026年3月27日

首先提交符合 QC 标准的

2026年3月27日

首次发布 (实际的)

2026年4月2日

研究记录更新

最后更新发布 (实际的)

2026年9月22日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年3月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅